We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Nemolizumab improved atopic dermatitis-induced lesions ...

Please provide your email address to receive an email when new articles are posted on . More than a quarter of patients achieved IGA clear or almost clear as well as a 2-grade improvement from ...

Nemolizumab, an interleukin 31 receptor antagonist, was well tolerated and significantly improved inflammation and pruritus in patients with moderate to severe atopic dermatitis (AD). "Nemolizumab ...

A small study recently found that the experimental drug nemolizumab (Mitchga) substantially improved itching in people with atopic dermatitis (AD). These improvements, in turn, were associated with ...

The European Commission has approved nemolizumab (Nemluvio) for subcutaneous use in treating moderate to severe atopic dermatitis (AD) in patients aged ≥ 12 years and moderate to severe prurigo ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...

The FDA has granted nemolizumab Priority Review for the treatment of prurigo nodularis. The Food and Drug Administration (FDA) has accepted for review the Biologics License Applications (BLA) for ...

Galderma has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia, ...

Nemolizumab is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signalling of IL-31. 2,5,6 IL-31 is a neuroimmune cytokine that drives itch and ...

Nemluvio demonstrated long-term improvements in itch intensity, skin lesions and quality of life The OLYMPIA LTE study was designed to assess the safety and efficacy of Nemluvio in patients with ...

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a ...

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the ...